|MDACC Study No:||2012-0262 (clinicaltrials.gov NCT No: NCT01702155)|
|Title:||A Phase I/II Study of DFP-10917 Given by Continuous Infusion in Patients with Relapsed or Refractory Acute Leukemia|
|Principal Investigator:||Hagop Kantarjian|
|Study Description:||The goal of this clinical research study is to find the highest tolerable dose |
of DFP-10917 that can be given to patients with relapsed or refractory
leukemia. The safety of the study drug will also be tested.
DFP-10917 is designed to insert itself into the DNA of leukemia cells. It may
stop these cells from reproducing and may cause the DNA strands to break. This
may cause leukemia cells to die.